Immunophotonics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
Phase 1
Active, not recruiting
- Conditions
- Metastatic Solid TumorColon CancerNonsmall Cell Lung CancerSoft Tissue Sarcoma
- Interventions
- Drug: 1.0% IP-001 for Injection
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Immunophotonics, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05688280
- Locations
- 🇺🇸
Miami Cardiac & Vascular Institute, Coral Gables, Florida, United States
🇺🇸University of Louisville Physicians, PSC, Louisville, Kentucky, United States
🇺🇸Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
News
No news found